https://www.selleckchem.com/pr....oducts/bms-927711.ht
The patient received the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (100 mg, three times weekly). After 12 wk of treatment, the patient's hemoglobin increased significantly, and her symptoms were alleviated. During the follow-up period, adverse drug reactions were controllable and tolerable. Oral roxadustat is effective and tolerable for the treatment of ESA hypores-ponsiveness-related anemia inpatients undergoinghemodialysis. Oral roxadustat is effective and tolerable for the treatment of ESA hypores-ponsivenes
Like
Comment
Share
